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Background: miR-200b has been reported to be a tumor suppressor and a promising therapeutic target in cancer.
miR-200b has been associated with epithelial-mesenchymal transition and chemo-resistance in cancer. The aim of
this study is to investigate the expression of miR-200b, its prognostic roles and its potential targets in breast cancer.
Methods: qRT-PCR was used to detect miR-200b expression in breast cancer tissues and cell lines. In situ
hybridization of miR-200b on tissue microarray including 134 breast cancer samples was used to evaluate its
prognostic role. Novel targets of miR-200b in breast cancer were predicted and confirmed by luciferase reporter
assay and western bloting. Immunohistochemical staining was used for protein detection. The biological effects of
miR-200b in breast cancer cells were further confirmed by ectopic expression of its mimics followed by MTT assay
and invasion test.
Results: miR-200b was downregulated in breast cancer tissues and cell lines and its low-expression correlated with
poor outcome in breast cancer patients. Members of RAB family, RAB21, RAB23, RAB18 and RAB3B were predicted
to be the targets of miR-200b. The luciferase reporter assay was performed to certificate this prediction. The
expressions of RAB21, RAB23, RAB18 and RAB3B were suppressed by transfection of miR-200b in breast cancer cells.
Over-expression of miR-200b or knock-down of RAB21, RAB23, RAB18 and RAB3B inhibited breast cancer cell
proliferation and invasion in vitro.
Conclusions: Our study provides evidence that miR-200b is a prognostic factor in breast cancer targeting multiple
members of RAB family. MiR-200b could be a potential therapeutic target in breast cancer.
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Breast cancer is the first ranked female malignancy
worldwide, with about 200,000 new incidence and 40,000
deaths per year in US [1]. Generally breast cancers could
be classified according to the TNM staging system [2] and
their molecular groups [3], which include luminal A type
(estrogen receptor (ER) + and/or progesterone receptor
(PR) +, human epidermal growth factor receptor-2
(HER2)-), luminal B type (ER + and/or PR+, HER2+),
HER2 over-expressing type (ER-, PR-, and HER2+), basal-* Correspondence: xiexm@sysucc.org.cn
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stated.like type (ER-, PR-, HER2-, cytokeratin 5/6+, and/or epi-
dermal growth factor receptor (EGFR)+). Breast cancer of
HER2 over-expressing or basal-like type would predict
more recurrence, distant metastasis, and therapy resist-
ance [4]. The comprehensive therapy and prognosis for
breast cancer would depend on both the TNM stage and
molecular subtype. Although breast cancers with early
stage show excellent outcome after therapy, recurrent and
metastatic breast cancer patients remain big problems for
cure [5].
MicroRNAs, also termed miRNAs, are a class of en-
dogenous, non-protein coding single-stranded RNA mole-
cules with a length of 21–23 nucleotides, which plays a
crucial role in the post-transcriptional regulation of gene
expression [6]. miRNAs are highly conserved and specific,
and regulate gene expression by binding to the 3′ untrans-
lated region (UTR) of target messengerRNA (mRNAs)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mRNAs. miRNAs has been proved to play vital roles in
cancer management, acting as either oncogenes or tumor
suppressors [7].
The miR-200 family (including miR-200a, miR-200b,
miR-200c, miR-141 and miR-429) are transcribed from
two chromosomal locations: miR-200b-200a-429 cluster
at chromosomal location 1p36 and miR-200c-141 cluster
at chromosomal location 12p13 [8]. Recently, the miR-
200 family has been associated with carcinogenesis and
cancer therapy [9]. Dysregulation of the miR-200 family
was reported in several malignancies, including ovarian,
endometrial, lung and gastric cancer [10-12]. The miR-
200 family has been supposed to be tumor suppressors
regulating epithelial-mesenchymal transition (EMT)
[13]. miR-200 directly targets EMT-inducing transcrip-
tional factors ZEB1 and ZEB2, which repress E-cadherin
expression. miR-200 could also suppress β-catenin/Wnt
signaling pathway by targeting β-catenin mRNA [14],
thus highlighting its roles in cancer invasion and metas-
tasis. Moreover, mi-200 has been reported to affect the
chemotherapy and endocrine thrapy resistance in breast
cancer [15,16]. Among the miR-200 family, miR-200b is
thought to be the fundamental regulator in EMT and
cancer chemo-sensitivity [17]. However, the expression
of miR-200b and its prognostic role in breast cancer
remain unclear.
In this study, we investigated the expression of miR-
200b and its prognostic roles in breast cancer patients,
predicted and further identified multiple members of
RAB family as new targets of miR-200b in breast cancer.
Materials and methods
Cell lines and culture
Human mammary epithelial (HME) cell line 184A,
MCF-10A, human breast cancer cell lines MDA-MB-
231, MDA-MB-435, MCF-7, T47D, BT-474, BT-483, and
mouse breast cancer cell line 4 T1 were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and were passaged in our laboratory for less than six
months after resuscitation of frozen aliquots. The breast
cancer cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, CA, USA) supplemented
with 10% fetal bovine serum (FBS, GIBCO, Cappinas,
Brazil), in a humidified incubator at 37°C containing 5%
CO2. All cell lines were re-authenticated by short tandem
repeat DNA profiling every 6 months after used.
Quantitative real-time polymerase chain reaction analysis
(qRT-PCR)
Expression level of miR-200b was detected in both
breast cancer tissues and cell lines. 40 pairs of tumor
tissues and para-carcinoma tissues from breast cancer
patients were obtained. Human mammary epithelial cellline 184A, MCF-10A, and several breast cancer cell lines
were also included. Total RNAs were extracted from
tissues/cells with TRIzol reagent (Invitrogen). For miR-
200b, reverse transcription and qRT-PCR reactions were
performed by means of a SYBR-green-containing PCR
kit (GenePharma, Shanghai, China). U6 snRNA was used
as an endogenous control for miRNA detection. The
expression of miR-200b was quantified by measuring
cycle threshold (Ct) values and normalized using the
2-ΔΔCt method relative to U6 snRNA.
Patients and specimens for tissue microarray
A total of 134 female breast cancer patients who were
diagnosed by histo-pathology in Sun Yat-Sen University
Cancer Center from October 2001 to September 2006
were obtained. Specimens were formalin-fixed and em-
bedded in paraffin by standard methodology after obtained
during surgery and were stored in the Department of
Specimen and Resource in Sun Yat-Sen University Cancer
Center. IHC of ER, PR, and HER-2 status were performed
in the Pathology Department of Sun Yat-Sen University
Cancer Center. All the patients included in present study
did not receive any chemotherapy and radiation therapy
before, and their complete clinico-pathological data, inclu-
ding age, histological type, lymph nodes status, tumor size,
stage, local relapse, distant metastatic relapse, ER status,
PR status and HER-2 status, were available and reviewed.
Histological type, reclassified according to the WHO
classification and stage of tumor, was based on the TNM
staging system (American Joint Committee on Cancer
classification). Follow-up was updated by review of records
and telephone calls. The date of death and the date of
relapse were used to calculate estimate overall survival
(OS) and disease-free survival (DFS).
This study was approved by the Ethics Committee of
SunYat-Sen University Cancer Center Health Authority.
The collection and use of tissues followed the proce-
dures that are in accordance with the ethical standards
as formulated in the Helsinki Declaration.
Tissue microarray (TMA) construction
Representative part of the breast cancer specimens used
for creating tissue microarray were selected by two experi-
enced pathologists, using hematoxylin and eosin–stained
sections which were formalin-fixed and embedded in
paraffin as mentioned above. TMA block was con-
structed with MiniCore Control Station (ALPHELYS
SARL, France) and designed by TMA Designer tissue
array design software (ALPHELYS SARL, France). We
used 1.0-mm core tissue biopsies and took tissues
from paraffin-embedded tissue blocks to two new recipi-
ent blocks (one contained 51 samples, and the other 83
samples), and one core per case was arrayed. The recipient
blocks were cut and placed on slides.
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miR-200b miRCURYTM LNA custom detection probe
(Exiqon, Vedbaek, Denmark) was used for ISH. The 5′-
3′ sequences (enhanced with LNA) were TCATCATT
ACCAGGCAGTATTA with a digoxigenin (DIG) label at
both the 5′ and 3′ ends.
In situ hybridization of miR-200b and scoring system
After deparaffinized, the slides were mounted onto
flow through slide chambers and placed in a Tecan
Freedom Evo automated hybridization instrument (Tecan,
Männedorf, Switzerland) in which the following steps
were performed: proteinase-K treatment 15 μg/ml at 37°C
for 8 min, pre-hybridization in Exiqon hybridization buffer
(Exiqon, Vedbæk, Denmark) at 62°C for 15 min, hybri-
dization with 40 nM miR-200b probe, stringent washes
with 5 × SSC, 1 × SSC and 0.2 × SSC buffers at 62°C
over 33 min, DIG blocking reagent (Roche, Mannheim,
Germany) in maleic acid buffer containing 2% sheep
serum at 30°C for 15 min, Streptavidin-HRP -conjugated
anti-digoxigenin (diluted 1:500 in blocking reagent, Roche)
at 30°C for 30 min. After washing, the slides were incu-
bated in DAB at 25°C for 3-5 min. The slides were then
dismantled in water, dehydrated in alcohol solutions
and mounted with eukitt mounting medium (VWR,
Herlev, Denmark).
The intensities of miR-200b staining was scored by
0–4, according to the standards of 0–1 (no staining),
1–2 (weak staining), 2–3 (medium staining) and 3–4
(strong staining). The percentages of miR-200b cells
of individual samples were analyzed. Those expression
scores equaled to the intensities * the percentages, and the
maximum was 4 and the minimum was 0. Individual
samples were evaluated by at least two pathologists in a
blinded manner, and those expression scores of greater
than 2 were defined high expression, otherwise the expres-
sion scores were low.
Immunohistochemical (IHC) staining and scoring system
The Labeled StreptAvidin Biotin Method was used for
IHC in our study. After deparaffinizing and rehydrating,
the slides were treated with 90% methanol/3% H2O2
solution for 15 min at room temperature to block endo-
genous peroxidase. Then, the slides were soaked in
sodium citrate buffer (10 mM Sodium citrate, 0.05%
Tween 20, pH 6.0) under 96°C for 5 min for antigen
retrieval. After blocking by BSA, the following antibodies
were used: mouse monoclonal antibody for RAB21 (sc-
81917), rabbit polyclonal antibody for RAB23 (sc-130248)
and RAB3B (sc-305), goat polyclonal antibody for RAB18
(polyclonal antibody for RAB) (Santa Cruz Biotechnology).
We added antibodies to the slides for overnight storage at
4°C and then incubated the slides at room temperature
with biotinylated secondary antibody for 20 min, andfinally HRP-Streptavidin for 15 min. After DAB staining,
the results were graded for intensity (0-negative, 1-weak,
2-moderate, and 3-strong) and percentage of positive cells
(0, 1 (1–24%), 2 (25–49%), 3 (50–74%), and 4 (75–100%))
with discrepancies resolved by consensus. The grades were
multiplied to determine a score. The scores of tumors
were defined as the following rule: negative (score = 0–3)
and positive (score > =4).
Construction of luc-UTR vectors
The full-length RAB21, RAB23, RAB18, RAB3B, RAB37,
RAB8B, RAB7A, RAP1B, RAP2C 3′-UTR was cloned
into the EcoRIand HindIII sites of the pMIR-REPORT
luciferase vector (Ambion, Austin, TX, U.S.) using PCR
generated fragment. A Luc-mut vector of RAB21, RAB23,
RAB18, and RAB3B in which the first seven nucleotides
complementary to the miR-200b seed-region were mu-
tated by site-directed mutagenesis (Stratagene) served as a
mutant control.
Luciferase assay
Luc-wt, Luc-mut, and Luc-ctrl were co-transfected
within vitro-produced miR-200b into MDA-MB-231 cells.
The pMIR-REPORT β-galactosidase control vector was
transfected and served as a control. Luciferase activity
was measured in cell lysates 48 h after transfection
using a dual-light luminescent reporter gene assay kit
(Applied Biosystems). Results were normalized against
β-galactosidase activity.
Western blot
Cell protein lysates, cytosol protein or nuclear protein was
separated in 10% SDS-polyacrylamide gels, electrophoret-
ically transferred to polyvinylidene difluoride membranes
(Millipore), then detected with mouse monoclonal anti-
body for RAB21 (sc-81917), rabbit polyclonal antibody for
RAB23 (sc-130248) and RAB3B (sc-305), goat polyclonal
antibody for RAB18 (polyclonal antibody for RAB) (Santa
Cruz Biotechnology), mouse monoclonal antibody for β-
actin (Abcam) and commercial ECL kit (Pierce). The
intensity of protein fragments was quantified using
Chemical DocTM XRS + (Bio-Rad).
RNA silencing for RAB21, RAB23, RAB18, and RAB3B
The sense sequences of siRNA oligonucleotides targeting
the RAB18, RAB21, RAB23, and RAB3B transcripts,
respectively, were as follows: si- RAB18: 5′-UUCUGG
UUGUAACUUCACGGCT-3′; si- RAB21: 5′-UUAAUA
GGUUGGAUGGCGGTT-3′; si- RAB23: 5′-CUUCAC
TACUGCUUCGAGTT-3′; and si- RAB3B: 5′-AUAA
CUUGGAGGGACUGCCTT-3′ (Invitrogen). Scrambled
siRNA was used as a negative control. Cells were plated in
culture dishes or in 24-well plates for 24 h, and transfected
Figure 1 miR-200b was down-regulated in breast cancer tissues and cell lines. (A) The expression of miR-200b was detected by qRT-PCR in
40 pairs of normal mammary tissues and breast cancer samples. (B) The expression of miR-200b was detected by qRT-PCR in breast cancer cell lines.
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cells were harvested for use in other assays.
MTT assay
Cell viability was examined by the 3-(4, 5-dimethyl-
thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay. Cells transfected with either scramble or miR-Figure 2 miR-200b as a prognostic factor in breast cancer patients. (A
Two miR-200b high samples and two miR-200b low samples were shown as
miR-200b high ISH staining samples and three miR-200b low samples. (C) Sur
miR-200b expression correlated with worse outcome.200b mimics were seeded at a density of 5,000 cells per
well in 96-well plates and incubated at 37°C for 24 h. Cells
were then incubated an additional 72 h, and the MTT
assay was performed according to the manufacturer’s in-
structions (Molecular Probes, Eugene, OR). Absorbance
values were determined at 570 nm on a Spectra Max 250
spectrophotometer (Molecular Devices, Sunnyvale, CA).) The ISH staining of miR-200b in breast cancer tissue microarray: ×200.
representatives. (B) qRT-PCR results for miR-200b detection in three
vival curves of OS and DFS according to miR-200b expression. Low
Table 1 Clinico-pathological variables and the expression
of miR-200b in total breast cancer patients




(n = 56) P value
No. % No. %
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The cell invasion assay was conducted as described pre-
viously [18]. Briefly, cells were seeded onto the basement
membrane matrix present in the insert of a 24-well cul-
ture plate (EC matrix, Chemicon, Temecula, CA). Fetal
bovine serum was added to the lower chamber as a
chemoattractant. After an additional 48 hours, the non-
invading cells and EC matrix were gently removed with
a cotton swab. Invasive cells located on the lower side of
the chamber were stained with crystal violet, counted
and imaged.Age (years) 0.330
<50 82 46 56.1 36 43.9
>50 52 32 61.5 20 38.5
Menopause 0.524
Yes 63 37 58.7 26 41.3
No 71 41 57.7 30 42.3
LN infiltrated 0.148
Yes 80 50 62.5 30 37.5
No 54 28 51.9 26 48.1
Tumor size (cm) 0.080
= < 2 38 18 47.3 20 52.7
>2 96 60 62.5 36 37.5
TNM stage 0.040*
I-II 78 40 51.3 38 48.7
III- IV 56 38 67.9 18 32.1
Local relapse 0.083Statistical analysis
Data are presented as mean ± SD from at least three
separate experiments. Multiple group comparisons were
performed using ANOVA with a post hoc test for
subsequent individual group comparisons. The distinct
expression of miR-200b between tumor tissues and para-
carcinoma tissues was examined by independent samples
T-test. The relationships between miR-200b expression
and clinico-pathological parameters were examined by
chi-square test. Overall survival (OS) or disease-free sur-
vival (DFS) curves were calculated by the Kaplan-Meier
method and the log-rank test was used to determine
the difference in OS or DFS rates between two groups.
Results were considered statistically significant when
P ≤ 0.05 was obtained. All the statistical analyses were
performed using SPSS13.0 for Windows (SPSS Inc.,
Chicago, IL, USA).Yes 8 7 87.5 1 12.5




Yes 34 27 79.4 7 20.6
No 100 51 61.0 49 49.0
ER status 0.155
Positive 51 33 64.7 18 35.3
Negative 83 45 54.2 38 45.8
PR status 0.073
Positive 54 36 66.7 18 33.3
Negative 80 42 52.5 38 47.5
HER-2 status 0.213
Positive 22 15 68.2 7 31.8
Negative 112 63 56.3 49 43.8
TNBC status 0.472
TNBC 51 29 56.9 22 43.1
Non-TNBC 83 49 59.0 34 41.0
*means statistically significant (p < 0.05).
% means percentage within the row.
TNBC, triple-negative breast cancer, means ER(−), PR(−), HER-2(−). High
expression of miR-200b was seen in 41.8% of total patients and correlated
with early TNM stage (p = 0.040) and fewer metastasis (p = 0.003).Results
The expression of miR-200b in breast cancer tissues and
cell lines
To evaluate the expression of miR-200b in breast cancer
tissues, qRT-PCR was used to detect the expression level
in 40 pairs of tumor tissues and para-carcinoma (normal)
tissues from breast cancer patients. The results showed
that expression of miR-200b in breast cancer tissues was
significantly lower than in normal tissues (Figure 1A). In
comparison with the normal tissues, miR-200b was down-
regulated in 77.5% (31/40) of the tumor samples. We
further detected expression of miR-200b in cell lines
(Figure 1B), including human mammary epithelial (HME)
cell lines (184A, MCF-10A), human breast cancer cell
lines (MDA-MB-231, MDA-MB-435, MCF-7, T47D,
BT-474, BT-483), and mouse breast cancer cell line
4 T1. Compared with 184A and MCF-10A, miR-200b
was down-regulated in MCF-7, MDA-MB-435, T47D,
BT-483, MDA-MB-231, and 4 T1, especially in the latter
two cell lines. These results revealed that reduced miR-
200b expression was a frequent event in human breast
cancer tissues and could be involved in breast cancer
carcinogenesis.The relationships between expression of miR-200b and
clinical parameters in breast cancer patients
We further evaluated the prognostic role of expression
of miR-200b in breast cancer patients by in situ hybri-
dization (ISH) staining on tissue microarray. MiR-200b
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the cytoplasm. Two miR-200b high samples and two
miR-200b low samples were shown as representatives
(Figure 2A). To confirm the miR-200b ISH staining
results, we extracted total RNAs form three miR-200b
high samples and three miR-200b low samples for
qRT-PCR (Figure 2B). The PCR results showed that
the ISH staining could reflect the relative level of miR-
200b expression in the samples. The clinico-pathologic
characteristics and miR-200b expression of the breast
cancer patients involved in our study are shown in Table 1.
In all 134 breast cancer patients, high expression of
miR-200b was seen in 41.8% of total patients. High
miR-200b expression correlated with early TNM stage
(p = 0.040) and fewer metastasis (p = 0.003). Further-
more, markedly reduced overall survival (p = 0.0030)
and disease-free survival (p = 0.0000) were observed in the
breast cancer patients who had low miR-200b expression
compared with the patients who exhibited high expres-
sion levels (Figure 2C). In our study, the estimate
overall survival and disease-free survival for miR-200b
high patients were 109.3 months and 101.2 months, while
the two for miR-200b low patients were 78.3 months and
66.2 months respectively. These results indicated that
miR-200b could be a prognostic factor in breast cancer
patients.Figure 3 RAB21, RAB23, RAB18 and RAB3B is a direct target of miR-2
RAB37, RAB8B, RAB7A, RAP1B and RAP2C. Predicted binding between miR-
Luciferase reporter assays 48 h after transfection with indicated pMIR-Repo
with miR-200b mimics, or relevant scramble controls. Luciferase activities w
pMIR-Report plasmids of RAB21, RAB23, RAB18 and RAB3B. Mutation in the
were the mean ± s.d. of six replicates and were representative of three inde
of RAB21, RAB23, RAB18 and RAB3B. Western blot analyzed their expression
MDA-MB-231 and 4 T1 cells.miR-200b targeted multiple members of RAB family
To determine the function of miR-200b in breast cancer,
we used online softwares TargetScan to search for
potential miR-200b target genes. We found that mem-
bers of RAB family are among these candidate target
genes. A miR-200b-binding site was found in the 3′-
UTR of RAB21, RAB23, RAB18, RAB3B, RAB37, RAB8B,
RAB7A, RAP1B, RAP2C mRNA with perfect base pairing
(Figure 3A). To verify whether these genes were direct
targets of miR-200b, we subcloned the full-length 3′-UTR
of RAB21, RAB23, RAB18, RAB3B, RAB37, RAB8B,
RAB7A, RAP1B, RAP2C into the luciferase reporter
vector. However, addition of in vitro-produced miR-200b
only suppressed the luciferase activity of the 3′-UTR of
RAB21, RAB23, RAB18 and RAB3B upon co-transfection
of the luciferase vector (wild-type, mutant, or negative con-
trol) with the in vitro-produced microRNAs (miR-200b
mimics or scramble control) into MDA-MB-231 cells
(Figure 3B). This inhibition was abolished when the seed
sequences of the miR-200b target sequences were mutated
in the Luc-mut vector (Figure 3B). To directly assess the
effects of miR-200b on the expression of RAB21, RAB23,
RAB18 and RAB3B, we transfected miR-200b mimics into
MDA-MB-231 and 4 T1 cells and found that overex-
pression of miR-200b reduced mRNA and protein level of
RAB21, RAB23, RAB18 and RAB3B (Figure 3C).00b. (A) miR-200b binds to the 3′UTRs of RAB21, RAB23, RAB18, RAB3B,
200b and the seeds match in the nine predicted genes’ 3′UTRs. (B)
rt plasmids and a renilla transfection control plasmid, co-transfected
ere significantly inhibited on co-transfection of miR-200b mimics and
corresponding binding sites abolished this inhibition. Data shown
pendent experiments. *P < 0.05 (C) miR-200b regulated the expression
48 h after transfection with miR-200b mimics or scramble control in
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RAB21, RAB23, RAB18 and RAB3B in breast cancer tissues
To evaluate the associations between expression of miR-
200b and RAB21, RAB23, RAB18 and RAB3B in breast
cancer tissues, we further detected expression of miR-
200b by ISH staining and expression of RAB21, RAB23,
RAB18 and RAB3B protein by immunohistochemistry
(IHC) staining in 10 pairs of tumor tissues and para-
carcinoma tissues from breast cancer patients, who had
developed distant metastasis after operation. As shown
in Figure 4, compared with normal breast tissue, miR-
200b expression was down-regulated in tumor tissue,
while the contrary situations were found for RAB21,
RAB23, RAB18 and RAB3B IHC staining. In summary,
miR-200b low ISH staining was seen in 90% (9/10)
tumor samples, while positive rates for RAB21, RAB23,
RAB18 and RAB3B IHC staining were 80%, 80%, 90%,
100% respectively. These results further confirmed theFigure 4 IHC staining of RAB21, RAB23, RAB18 and RAB3B in human
from breast cancer patients, who had developed distant metastasis after op
miR-200b expression was down-regulated in tumor tissue, while the contraregulation of RAB21, RAB23, RAB18 and RAB3B pro-
teins by miR-200b in breast cancer tissues.
Over-expression of miR-200b or knock-down of RAB21,
RAB23, RAB18 and RAB3B inhibited breast cancer cell
proliferation and invasion
To assess the biological effects of over-expressing
miR-200b in breast cancer cells, ectopic expression of
miR-200b mimics were transfected into MDA-MB-231
and 4 T1 cells. Transfection of miR-200b mimics in
MDA-MB-231 and 4 T1 cells markedly attenuated cell
proliferation, compared with scramble (Figure 5A). More-
over, ectopic expression of miR-200b mimics in MDA-
MB-231 and 4 T1 cells markedly attenuated cell invasion
compared with control cells (Figure 5B, C). To identify
the biological effects of RAB21, RAB23, RAB18 and
RAB3B, specific siRNAs for each were also synthesized.
Transfection of siRNAs for RAB21, RAB23, RAB18 andbreast cancer tissues. 10 pairs of tumor tissues and normal tissues
eration, were detected by ISH or IHC. Compared with normal tissue,
ry situations were found for RAB21, RAB23, RAB18 and RAB3B.
Figure 5 Over-expression of miR-200b or knock-down of RAB21, RAB23, RAB18 and RAB3B inhibits breast cancer cell proliferation and
invasion. (A) Transfection of miR-200b mimics or knock-down of RAB21, RAB23, RAB18 and RAB3B in MDA-MB-231 and 4 T1 cells markedly
attenuated cell proliferation: MTT assay at 24 h, 48 h and 72 h after transfection. (B, C) Transfection of miR-200b mimics or knock-down of RAB21,
RAB23, RAB18 and RAB3B in MDA-MB-231 and 4 T1 cells inhibited cell invasion: Data shown in Figure B were the mean ± s.d. of three replicates
and were representative of three independent experiments. *P < 0.05. The representing images were shown in Figure C.
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invasion (Figure 5A, B, and C). These results indicated
that the biological effects of miR-200b in breast cancer
cells may attribute to regulation of RAB21, RAB23,
RAB18 and RAB3B, and thus miR-200b could be a thera-
peutic target in breast cancer.
Discussion
The miR-200 family has been reported to be a funda-
mental regulator of EMT, thus highlighting their roles in
cancer progression. As a founding member in miR-200
family, miR-200b attracts much focus both in carcino-
genesis and cancer therapy in recent years [17]. Down-
regulation of miR-200b has been observed in renal cell
carcinoma [19]. miR-200b as tumor suppressor regulat-
ing EMT has bee reported in several malignancies, such
as prostate cancer [20], colon cancer [21], non-small cell
lung cancer [22], and so on. The dysregulation of miR-
200b in cancer could be transcriptional inhibition or
epigenetic modifications, such like DNA methylationand histone modifications [23,24]. Moreover, miR-200b
is thought to be related to cell differentiation by target-
ing GATA-4 [25]. Loss of miR-200b contributes to the
breast cancer stem cell status maintaining [26]. Besides,
miR-200b has also been associated with cancer chemo-
sensitivity by modulating PTEN, PTPN12 and thus their
downstream oncogenes like src and ras [27,28].
In this study, we investigated the expression of miR-
200b and its prognostic role in breast cancer. We
showed that expression of miR-200b was significantly
lower in breast cancer tissues than normal tissues. Similar
results were found in breast cancer cell lines. In addition,
we analyzed the prognostic role of the expression of miR-
200b in breast cancer patients. We found that low expres-
sion of miR-200b correlated with advanced clinical stage
and more distant metastasis in breast cancer. Since
miR-200b was reported as a regulator of EMT, which
was thought to be the initiation of metastasis, the re-
sults were reasonable. Further we showed that the patients
with low miR-200b expression correlated with worse
Ye et al. Journal of Translational Medicine 2014, 12:17 Page 9 of 10
http://www.translational-medicine.com/content/12/1/17outcome, indicating miR-200b as a tumor suppressor
in breast cancer.
We predicted the targets of miR-200b in breast
cancers. Besides previously reported ZEB1/ZEB2, we
found multiple members of RAB family were also poten-
tial targets of miR-200b. We then performed the lucif-
erase report assay to identify RAB21, RAB23, RAB18
and RAB3B as novel direct targets of miR-200b. The
regulations of RAB21, RAB23, RAB18 and RAB3B by
miR-200b were further confirmed in breast cancer
cell lines.
RAB family proteins belong to the large Ras superfamily
of small GTPases [29]. There are more than 60 members
in RAB family in humans, which are specifically local-
ized to subcellular membrane compartments, regulating
intracellular membrane transport. By switching between
inactive cytosolic GDP-bound forms and active mem-
brane-associated GTP-bound forms, RAB proteins could
control endocytosis, protein secretion, recycling and
degradation, thus acting as key regulators of intracellular
trafficking [30]. Recent studies have provided emerging
evidences for involvement of RAB proteins in tumour
progression. More and more members of RAB family have
been reported to be dysregulated in cancers, either as on-
cogenes or tumor suppressors [31]. Several RAB proteins
have been linked with tumor migration, invasion and drug
resistance. Among them, up-regulation of Rab3B is re-
ported in prostate cancer, promoting cancer cell survival
[32]. Rab21 is associated with the control of integrin traf-
ficking, thus modulating adhesion and motility in breast
cancer cells [33]. Another RAB family member, RAB23
has been identified as an antagonist of Sonic Hedge-
hog signaling pathway which is deregulated in many
cancers [34], and found to over-expressed in gastric
and liver cancer [35].
In our study, we identified RAB21, RAB23, RAB18
and RAB3B as novel direct targets of miR-200b in
breast cancers. Over-expression of miR-200b or knock-
down of the four RAB proteins significantly inhibited
breast cancer cell proliferation and invasion. However,
whether the tumor suppressing effects of miR-200b in
breast cancer depends dominatingly or partially on its
regulation of RAB proteins needs more investigation.
Conclusion
In summary, our study demonstrated that miR-200b
could be a tumor suppressor and a potential biomarker
in breast cancer patients. Members of RAB family,
RAB21, RAB23, RAB18 and RAB3B were novel targets
regulated by miR-200b in breast cancer, which could be
of promising therapeutic significance.
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